Department of Clinical , Social and Administrative Sciences, College of Pharmacy, University of Michigan, 428 Church Street, AnnArbor, MI 48109-1065, USA.
J Dermatolog Treat. 2012 Jun;23(3):196-202. doi: 10.3109/09546634.2010.544708. Epub 2011 Jan 22.
The impacts of use of pharmacotherapy for psoriasis on patient outcomes and medication costs need further examination using up-to-date large nationally representative data.
To examine the impacts of patient demographics and medication use on patient's health status and associated medication costs.
A retrospective cross-sectional study was conducted using the 2007 Medical Expenditure Panel Survey (MEPS) database. Information on patient demographics, health status, medication utilization, and medication costs were obtained representing 543 231 patients with psoriasis.
Weighted multiple linear regression analyses indicated that the use of biological/systemic agents yielded an increase in patient health status among all types of medications (β = 7.9, p < 0.05). Use of biological/systemic agents also yielded an increase in annual medication spending (β = 2.5, p < 0.01). Use of biological agents was elevated compared to previous studies.
We observed an association between medication use for psoriasis treatment and its related patient health status and medication spending. The study findings could imply that encouraging the use of topical treatments may be an effective means to increase patient health status. The use of biologics needs further cost-effectiveness studies given the findings that biologics contribute to substantial increases in both drug expenditures and patient health status.
使用药物治疗银屑病对患者结局和药物费用的影响需要使用最新的全国代表性大型数据进一步研究。
检查患者人口统计学特征和药物使用对患者健康状况和相关药物费用的影响。
使用 2007 年医疗支出面板调查（MEPS）数据库进行回顾性横断面研究。获得了 543231 名银屑病患者的患者人口统计学、健康状况、药物使用和药物费用信息。
加权多元线性回归分析表明，生物/系统药物的使用增加了所有类型药物的患者健康状况（β=7.9，p<0.05）。生物/系统药物的使用也增加了年度药物支出（β=2.5，p<0.01）。与以往研究相比，生物制剂的使用有所增加。
我们观察到银屑病治疗药物使用与相关患者健康状况和药物支出之间存在关联。研究结果表明，鼓励使用局部治疗可能是提高患者健康状况的有效手段。鉴于生物制剂会导致药物支出和患者健康状况的大幅增加，生物制剂的使用需要进一步进行成本效益研究。
